Sanofi: Information concerning the total number of voting rights and shares - March 2025 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,452,461,656Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry und...
Sanofi: Informations relatives au nombre de droits de vote et d'actions – Mars 2025 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers SanofiSociété anonyme au capital de 2 452 461 656 euros Siège social : 46, avenue de la Grande Armée - 75017 Paris395 030 844 R.C.S. Paris DateNombre d’actions composant le capital Nombre réel de droits de vote (déduction faite des actions auto-détenues)Nombre théorique de droits de vote (y compris actions a...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: REDEIA. EUROPA: AIRBUS, BASF, ING, SOCIÉTÉ GÉNÉRALE. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 1T’25 que se publicarán en España y Europa en los próximos días. La macro desinfla las bolsas Jornada de caídas en Europa lastradas por los malos datos macro (PIB, ADP, PMI en EE.UU.) y en Europa (especialmen...
Press Release: Annual General Meeting of April 30, 2025 Annual General Meeting of April 30, 2025 Approval of the financial statements for the fiscal year 2024Distribution of a cash dividend of €3.92 per share, with payment as of May 14, 2025Board composition: renewal of four Directors and ratification of the cooptation of Jean-Paul Kress Paris, April 30, 2025. The Combined General Shareholders’ Meeting of Sanofi was held on April 30, 2025, under the chairmanship of Frédéric Oudéa. All resolutions submitted to the vote were adopted by the shareholders. The General Meeting approved the ind...
Communiqué de presse : Assemblée Générale Annuelle du 30 avril 2025 Assemblée Générale Annuelle du 30 avril 2025 Approbation des comptes sociaux et des comptes consolidés de l’exercice 2024Distribution d’un dividende en numéraire de 3,92 euros par action, dont la mise en paiement interviendra le 14 mai 2025Composition du Conseil d’administration : renouvellement de quatre administrateurs et ratification de la cooptation de Jean-Paul Kress Paris, le 30 avril 2025. L’Assemblée Générale Mixte des actionnaires de Sanofi s’est réunie le 30 avril 2025, sous la présidence de Frédéric Oudéa. Tou...
BNP PARIBAS SA: Disclosure for G-SIIs indicators as of 31 December 2024 Paris, 30 April 2025 Global systemically important institutions (G-SIIs) indicators for BNP Paribas Group as of 31 December 2024 are presented hereafter according to European Banking Authority (EBA) Implementing Technical Standards. The Basel Committee on Banking Supervision (BCBS) assesses the systemic importance of banks in a global context. The measurement approach of the global systemic importance is indicator-based. The methodology is outlined in “Global systemically important banks: updated assessment methodolo...
Communiqué de presse : Sanofi et CD&R finalisent la cession d’Opella et créent un leader mondial de la santé grand public Sanofi et CD&R finalisent la cession d’Opella et créent un leader mondial de la santé grand public Paris, le 30 avril 2025. Opella devient aujourd'hui un leader mondial indépendant de la santé grand public, marquant ainsi une étape décisive dans la stratégie de Sanofi. Sanofi annonce aujourd'hui la finalisation de la vente à CD&R d'une participation de contrôle de 50,0 % dans son activité de santé grand public Opella. Sanofi conserve une participation significative d...
Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader Sanofi and CD&R close Opella transaction, create global consumer healthcare leader Paris, April 30, 2025. Opella today becomes an independent global leader in consumer healthcare, marking a pivotal step in Sanofi's strategy. Sanofi announces today the closing of the sale to CD&R of a 50.0% controlling stake of its consumer healthcare business Opella. Sanofi retains a significant shareholding of Opella with a 48.2% stake. Bpifrance will own a 1.8% stake in Opella and will join the Board. The tr...
As expected, the focus during the call was concentrated on the potential tariff impact. Based on current tariff assumptions, ADS does not plan to increase prices unless: 1/ reciprocal tariffs are back to their initial levels after the 90-day pause,and 2/ the leading players, i.e. Nike, implement pr
Philips reported a slightly disappointing back end loaded FY25 outlook. We lower our estimates and cut our target price to €24 per share (from €25). We are below consensus for 1Q25. We stick to our HOLD rating as: (1) current trading conditions are weak; (2) significant restructuring and consent decree charges will continue to impact FCF and (3) valuation looks fair compared to peers.
Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race Paris, April 29, 2025. Sanofi is proud to unveil an exciting new chapter in its mission to fight meningitis, as it expands its partnership with McLaren Racing for a powerful activation alongside United Autosports, the official racing partner of McLaren Automotive. This unique collaboration will...
Communiqué de presse : Quand chaque seconde compte : Sanofi, McLaren Racing et United Autosports s'unissent pour sensibiliser à la méningite aux 24 Heures du Mans Paris, le 29 avril 2025. Sanofi est fière de présenter une nouvelle étape significative dans sa mission de lutte contre la méningite, en renforçant son partenariat avec McLaren Racing et United Autosports, le partenaire officiel de course de McLaren Automotive. Cette collaboration exceptionnelle mettra en lumière le Drapeau Méningite — un symbole puissant de la lutte mondiale contre cette maladie — qui sera fièrement a...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.